Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017
December 06 2017 - 7:30AM
Geron Corporation (Nasdaq:GERN) today announced that the company’s
analyst and investor meeting to discuss imetelstat clinical data
will take place in New York, N.Y., on Tuesday, December 19, 2017.
The presentation will begin at 8:30 a.m. ET.
Dr. Azra Raza, M.D., Professor of Medicine and Director of the
Myelodysplastic Syndromes (MDS) Center at New
York-Presbyterian/Columbia University Medical Center in New York
City, will present data from Part 1 of IMerge, the ongoing Phase
2/3 clinical trial of the telomerase inhibitor imetelstat in
patients with lower risk MDS being conducted by Janssen Research
& Development, LLC. These data have been accepted as a poster
presentation at the 59th American Society of Hematology (ASH)
Annual Meeting and Exposition.
A live audio webcast of the presentation will be available
through the Investors section of Geron’s website (www.geron.com)
under Events. Following the live presentation, the webcast will be
archived and available for replay for a period of 30 days.
To attend the meeting in person, please send an email to
Gitanjali Jain Ogawa at The Trout Group (gogawa@troutgroup.com) for
further information.
About the Collaboration with Janssen
On November 13, 2014, Geron entered into an exclusive worldwide
license and collaboration agreement with Janssen Biotech, Inc., to
develop and commercialize imetelstat for oncology, including
hematologic myeloid malignancies, and all other human therapeutics
uses. All regulatory, development, manufacturing and promotional
activities related to imetelstat are being managed through a joint
governance structure, with Janssen responsible for these
activities.
About Geron
Geron is a clinical stage biopharmaceutical company focused on
the collaborative development of a first-in-class telomerase
inhibitor, imetelstat, in hematologic myeloid malignancies. For
more information about Geron, visit www.geron.com.
CONTACTS:
Anna Krassowska, Ph.D.Investor and Media
Relations650-473-7765investor@geron.com or media@geron.com
Gitanjali Jain Ogawa The Trout Group 646-378-2949
gogawa@troutgroup.com
Geron (NASDAQ:GERN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2023 to Apr 2024